478 related articles for article (PubMed ID: 33211212)
41. Teriparatide vs. alendronate as a treatment for osteoporosis: changes in biochemical markers of bone turnover, BMD and quality of life.
Panico A; Lupoli GA; Marciello F; Lupoli R; Cacciapuoti M; Martinelli A; Granieri L; Iacono D; Lupoli G
Med Sci Monit; 2011 Aug; 17(8):CR442-448. PubMed ID: 21804463
[TBL] [Abstract][Full Text] [Related]
42. Anabolic therapy in glucocorticoid-induced osteoporosis.
Sambrook PN
N Engl J Med; 2007 Nov; 357(20):2084-6. PubMed ID: 18003966
[No Abstract] [Full Text] [Related]
43. The importance of assessing the rate of bone turnover and the balance between bone formation and bone resorption during daily teriparatide administration for osteoporosis: a pilot study.
Nakatoh S
J Bone Miner Metab; 2016 Mar; 34(2):216-24. PubMed ID: 26031934
[TBL] [Abstract][Full Text] [Related]
44. Efficacy and safety of 18 anti-osteoporotic drugs in the treatment of patients with osteoporosis caused by glucocorticoid: A network meta-analysis of randomized controlled trials.
Liu Z; Zhang M; Shen Z; Ke J; Zhang D; Yin F
PLoS One; 2020; 15(12):e0243851. PubMed ID: 33326444
[TBL] [Abstract][Full Text] [Related]
45. Romosozumab in postmenopausal women with low bone mineral density.
McClung MR; Grauer A; Boonen S; Bolognese MA; Brown JP; Diez-Perez A; Langdahl BL; Reginster JY; Zanchetta JR; Wasserman SM; Katz L; Maddox J; Yang YC; Libanati C; Bone HG
N Engl J Med; 2014 Jan; 370(5):412-20. PubMed ID: 24382002
[TBL] [Abstract][Full Text] [Related]
46. Efficacy of intravenous alendronate for the treatment of glucocorticoid-induced osteoporosis in children with autoimmune diseases.
Inoue Y; Shimojo N; Suzuki S; Arima T; Tomiita M; Minagawa M; Kohno Y
Clin Rheumatol; 2008 Jul; 27(7):909-12. PubMed ID: 18330609
[TBL] [Abstract][Full Text] [Related]
47. Denosumab is effective toward glucocorticoid-induced osteoporosis patients complicated with rheumatic diseases regardless of prior anti-osteoporotic drugs.
Iwamoto N; Okamoto M; Tsuji S; Endo Y; Takatani A; Shimizu T; Umeda M; Fukui S; Sumiyoshi R; Igawa T; Koga T; Kawashiri SY; Aramaki T; Ichinose K; Tamai M; Nakamura H; Origuchi T; Eguchi K; Ueki Y; Kawakami A
J Bone Miner Metab; 2019 May; 37(3):554-562. PubMed ID: 30187273
[TBL] [Abstract][Full Text] [Related]
48. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group.
Schnitzer T; Bone HG; Crepaldi G; Adami S; McClung M; Kiel D; Felsenberg D; Recker RR; Tonino RP; Roux C; Pinchera A; Foldes AJ; Greenspan SL; Levine MA; Emkey R; Santora AC; Kaur A; Thompson DE; Yates J; Orloff JJ
Aging (Milano); 2000 Feb; 12(1):1-12. PubMed ID: 10746426
[TBL] [Abstract][Full Text] [Related]
49. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass.
McClung MR; San Martin J; Miller PD; Civitelli R; Bandeira F; Omizo M; Donley DW; Dalsky GP; Eriksen EF
Arch Intern Med; 2005 Aug 8-22; 165(15):1762-8. PubMed ID: 16087825
[TBL] [Abstract][Full Text] [Related]
50. Glucocorticoid-induced osteoporosis and parathyroid hormone.
Carpinteri R; Porcelli T; Mejia C; Patelli I; Bilezikian JP; Canalis E; Angeli A; Giustina A; Mazziotti G
J Endocrinol Invest; 2010; 33(7 Suppl):16-21. PubMed ID: 20938221
[TBL] [Abstract][Full Text] [Related]
51. Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial.
Glüer CC; Marin F; Ringe JD; Hawkins F; Möricke R; Papaioannu N; Farahmand P; Minisola S; Martínez G; Nolla JM; Niedhart C; Guañabens N; Nuti R; Martín-Mola E; Thomasius F; Kapetanos G; Peña J; Graeff C; Petto H; Sanz B; Reisinger A; Zysset PK
J Bone Miner Res; 2013 Jun; 28(6):1355-68. PubMed ID: 23322362
[TBL] [Abstract][Full Text] [Related]
52. Comparison of once-weekly teriparatide and alendronate against new osteoporotic vertebral fractures at week 12.
Ikeda S; Nakamura E; Narusawa K; Fukuda F; Matsumoto H; Nakai K; Sakata T; Yoshioka T; Fujino Y; Sakai A;
J Bone Miner Metab; 2020 Jan; 38(1):44-53. PubMed ID: 31297652
[TBL] [Abstract][Full Text] [Related]
53. Effect of osteoporosis medication on changes in bone mineral density and bone turnover markers after 24-month administration of daily teriparatide: comparison among minodronate, raloxifene, and eldecalcitol.
Nakatoh S
J Bone Miner Metab; 2018 Mar; 36(2):221-228. PubMed ID: 28293779
[TBL] [Abstract][Full Text] [Related]
54. Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study: 12-month, randomized, placebo-controlled, double-blind and 12-month open-label phases.
Miyauchi A; Matsumoto T; Sugimoto T; Tsujimoto M; Warner MR; Nakamura T
Bone; 2010 Sep; 47(3):493-502. PubMed ID: 20580870
[TBL] [Abstract][Full Text] [Related]
55. Eldecalcitol is superior to alfacalcidol in maintaining bone mineral density in glucocorticoid-induced osteoporosis patients (e-GLORIA).
Matsumoto T; Yamamoto K; Takeuchi T; Tanaka Y; Tanaka S; Nakano T; Ito M; Tomomitsu T; Hirakawa A; Soen S
J Bone Miner Metab; 2020 Jul; 38(4):522-532. PubMed ID: 32140784
[TBL] [Abstract][Full Text] [Related]
56. [Effects of teriparatide and alendronate on bone mineral density of osteoporotic rats].
Li M; Jiao J; Meng XW; Xing XP; Xia WB; Zhou XY; Liu HC; Jiang Y; Wang O; Hu YY; Zhan ZW
Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(5):335-8. PubMed ID: 15854512
[TBL] [Abstract][Full Text] [Related]
57. Therapeutic effects of alendronate 35 mg once weekly and 5 mg once daily in Japanese patients with osteoporosis: a double-blind, randomized study.
Uchida S; Taniguchi T; Shimizu T; Kakikawa T; Okuyama K; Okaniwa M; Arizono H; Nagata K; Santora AC; Shiraki M; Fukunaga M; Tomomitsu T; Ohashi Y; Nakamura T
J Bone Miner Metab; 2005; 23(5):382-8. PubMed ID: 16133688
[TBL] [Abstract][Full Text] [Related]
58. Treatment responses with once-weekly teriparatide therapy for osteoporosis.
Shiraki M; Ueda S; Sugimoto T; Kuroda T; Nakamura T
Osteoporos Int; 2016 Oct; 27(10):3057-62. PubMed ID: 27234671
[TBL] [Abstract][Full Text] [Related]
59. Bone turnover markers to explain changes in lumbar spine BMD with abaloparatide and teriparatide: results from ACTIVE.
Eastell R; Mitlak BH; Wang Y; Hu M; Fitzpatrick LA; Black DM
Osteoporos Int; 2019 Mar; 30(3):667-673. PubMed ID: 30635696
[TBL] [Abstract][Full Text] [Related]
60. The impact of switching once-weekly teriparatide to denosumab in osteoporosis patients.
Miyagi M; Fujimaki H; Naruse K; Suto K; Inoue G; Nakazawa T; Imura T; Saito W; Uchida K; Shirasawa E; Takahira N; Takaso M
J Orthop Sci; 2019 Jan; 24(1):153-158. PubMed ID: 30146385
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
